NASDAQ Stock Market Gainers and Losers Post Earnings Reports

Strategic Insights -

Intel's robust first quarter earnings results, featuring a 25 percent revenue rise to $12.9 billion and adjusted profit of 59 cents a share, came as a relief to investors after Texas Instruments' disappointing earnings earlier. Yahoo!'s first quarter earnings also exceeded expectations, with a 6 percent revenue growth excluding traffic acquisition costs. The company's adjusted profit was 19 cents a share, up from 15 cents a share last year. In contrast, Cree, TriMas, Ceradyne, ViroPharma, and Veeco Instruments reported disappointing earnings, with their stocks experiencing significant declines in the after-market trading.

Key Takeaways:

  • Intel's first quarter revenue rose 25 percent to $12.9 billion, while adjusted profit was 59 cents a share, up from 43 cents a share last year.
  • Yahoo!'s first quarter earnings exceeded expectations, with revenue excluding traffic acquisition costs flat and adjusted profit of 19 cents a share.
  • Cree's fourth quarter earnings guidance fell below Street expectations, with the company expecting adjusted earnings of 25-31 cents a share and revenue of $225-245 million.
  • TriMas expects first quarter earnings from continuing operations of 32-35 cents a share, with sales growing 22-23 percent to $268-271 million.
  • Ceradyne's stock slid 2.97 percent to $43.30 after the company failed to meet Street expectations, with revenue declining 9.3 percent to $134.3 million.
  • ViroPharma's stock decreased 2.41 percent to $19 after the company reported a disappointing first quarter, with revenue declining 16.7 percent to $97.4 million.
  • Veeco Instruments' stock fell 2.24 percent to $45.47 after the company reported first quarter earnings of 64 cents a share, below Street expectations.

Statistics:

  • Intel's adjusted first quarter profit was $3.3 billion, up 23.4 percent from $2.7 billion last year.
  • Yahoo!'s revenue excluding traffic acquisition costs was $1.06 billion, a 6 percent decline from $1.15 billion last year.
  • Cree's third quarter adjusted earnings were $30.1 million or 27 cents a share, down from $51.3 million or 47 cents a share last year.
  • TriMas' sales are expected to grow 22-23 percent to $268-271 million in the first quarter.
  • Ceradyne's revenue declined 9.3 percent to $134.3 million in the first quarter.
  • ViroPharma's revenue declined 16.7 percent to $97.4 million in the first quarter.
  • Veeco Instruments' revenue declined 10.4 percent to $169.5 million in the first quarter.

Sources:

  • Intel Corp.
  • Yahoo! Inc.
  • Cree Inc.
  • TriMas Corp.
  • Ceradyne Inc.
  • ViroPharma Inc.
  • Veeco Instruments Inc.
  • International Data Corp. Semiconductor Application Forecaster
  • Texas Instruments Inc.
  • Microsoft Corp.
  • Deutsche Bank Securities Inc.